country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-132233

Copy Link Print Information

DDO-2093

DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC₅₀=8.6 nM; K_d=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.

For research use only. We do not sell to patients.

CAS No.: 2250024-74-7
Formula: C₂₉H₃₇ClFN₉O₃
Molecular Weight:614.11

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

DDO-2093 Chemical Structure

CAS No.: 2250024-74-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HUVEC	IC₅₀	>100 μM Compound: 24; DDO-2093	Cytotoxicity against HUVEC assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 34225179]
MOLM-13	IC₅₀	9.9 μM Compound: 24; DDO-2093	Antiproliferative activity against human MOLM-13 cells harboring MLL-AF9 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Antiproliferative activity against human MOLM-13 cells harboring MLL-AF9 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 34225179]
MOLM-13	GI₅₀	9.9 μM Compound: DDO-2093	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay	[PMID: 34283608]
MV4-11	IC₅₀	8 μM Compound: 24; DDO-2093	Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 34225179]
MV4-11	GI₅₀	8 μM Compound: DDO-2093	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay	[PMID: 34283608]
MV4-11	IC₅₀	8 μM Compound: DDO-2093	Anti-proliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as inhibition of cell viability treated for 72 hrs by CCK-8 assay Anti-proliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as inhibition of cell viability treated for 72 hrs by CCK-8 assay	[PMID: 35436124]

In Vitro

DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MV4-11 cells
Concentration:

1, 2.5, 5, and 10 μM
Incubation Time:

7 days
Result:

Dose-dependently reduced the mono-, di-, and trimethylation of H3K4.

In Vivo

DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female nude mice (MV4-11 human leukemia cancer xenografts)^[1]
Dosage:

20 mg/kg, 40 mg/kg and 80 mg/kg
Administration:

Intraperitoneal injection; every other day for 21 days
Result:

Had the tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.

Chemical Information

CAS No. 2250024-74-7
Appearance Solid
Molecular Weight 614.11
Formula C₂₉H₃₇ClFN₉O₃
Color White to off-white
SMILES

O=C(C1=CN(C2=CC=C(N3CCN(C)CC3)C(NC(C4=CC(N)=C(F)C(C)=C4Cl)=O)=C2)N=N1)NCCCN5CCOCC5
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chen W, et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity [published online ahead of print, 2021 Jun 28]. Eur J Med Chem. 2021;223:113677. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote